[1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
doi: 10.3322/caac.21492
|
[2] |
Pan M, Shi J, Yin S, et al. The effect and mechanism of LINC00663 on the biological behavior of glioma[J]. Neurochem Res, 2021, 46(7): 1737-1746. DOI: 10.1007/s11064-021-03311-3.
doi: 10.1007/s11064-021-03311-3
|
[3] |
李聪, 奚少彦, 陈银生, 等. 复发胶质瘤的病理学特征及其预后分析[J]. 中华神经外科杂志, 2020, 36(3): 227-231. DOI: 10.3760/cma.j.cn112050-20190727-00328.
doi: 10.3760/cma.j.cn112050-20190727-00328
|
[4] |
Li Y, Ma Y, Wu Z, et al. Advanced imaging techniques for differentiating pseudoprogression and tumor recurrence after immunotherapy for glioblastoma[J]. Front Immunol, 2021, 12:790674. DOI: 10.3389/fimmu.2021.790674.
doi: 10.3389/fimmu.2021.790674
|
[5] |
Wesseling P, Capper D. WHO 2016 classification of gliomas[J]. Neuropathol Appl Neurobiol, 2018, 44(2): 139-150. DOI: 10.1111/nan.12432.
doi: 10.1111/nan.12432
|
[6] |
Yang C, Lee DH, Mangraviti A, et al. Quantitative correlational study of microbubble-enhanced ultrasound imaging and magnetic resonance imaging of glioma and early response to radiotherapy in a rat model[J]. Med Phys, 2015, 42(8): 4762-4772. DOI: 10.1118/1.4926550.
doi: 10.1118/1.4926550
|
[7] |
Wu C, Su J, Wang X, et al. Overexpression of the phospholipase A2 group V gene in glioma tumors is associated with poor patient prognosis[J]. Cancer Manag Res, 2019, 11:3139-3152. DOI: 10.2147/CMAR.S199207.
doi: 10.2147/CMAR.S199207
|
[8] |
黄冠又, 张欣, 明悦, 等. 95例恶性胶质瘤患者术后生存情况及预后因素分析[J]. 重庆医学, 2016, 45(5): 664-666. DOI: 10.3969/j.issn.1671-8348.2016.05.028.
doi: 10.3969/j.issn.1671-8348.2016.05.028
|
[9] |
仇宇宁, 张静, 樊昊, 等. 胶质瘤患者术后复发时间相关因素研究及预后分析[J]. 医学与哲学, 2018, 39(16): 47-49. DOI: 10.12014/j.issn.1002-0772.2018.08b.14.
doi: 10.12014/j.issn.1002-0772.2018.08b.14
|
[10] |
Michaelsen SR, Christensen IJ, Grunnet K, et al. Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution[J]. BMC Cancer, 2013, 13:402. DOI: 10.1186/1471-2407-13-402.
doi: 10.1186/1471-2407-13-402
pmid: 24004722
|
[11] |
Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortality in China in 2013: an analysis based on urbanization level[J]. Chin J Cancer Res, 2017, 29(1): 1-10. DOI: 10.21147/j.issn.1000-9604.2017.01.01.
doi: 10.21147/j.issn.1000-9604.2017.01.01
|
[12] |
Henker C, Kriesen T, Scherer M, et al. Association between tumor compartment volumes, the incidence of pretreatment seizures, and statin-mediated protective effects in glioblastoma[J]. Neurosurgery, 2019, 85(4): E722-E729. DOI: 10.1093/neuros/nyz079.
doi: 10.1093/neuros/nyz079
|
[13] |
Han S, Liu Y, Li Q, et al. Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma[J]. BMC Cancer, 2015, 15:617. DOI: 10.1186/s12885-015-1629-7.
doi: 10.1186/s12885-015-1629-7
|
[14] |
王占伟. 全切除和次全切除对脑胶质瘤患者预后的影响分析[J]. 中国实用医药, 2015, 10(22): 55-56. DOI: 10.14163/j.cnki.11-5547/r.2015.22.032.
doi: 10.14163/j.cnki.11-5547/r.2015.22.032
|
[15] |
Kavouridis VK, Boaro A, Dorr J, et al. Contemporary assessment of extent of resection in molecularly defined categories of diffuse low-grade glioma: a volumetric analysis[J]. J Neurosurg, 2020, 133(5): 1291-1301. DOI: 10.3171/2019.6.JNS19972.
doi: 10.3171/2019.6.JNS19972
|
[16] |
刘博, 沈宏, 黄红星, 等. 脑胶质瘤复发的相关因素分析[J]. 浙江创伤外科, 2010, 15(2): 139-141. DOI: 10.3969/j.issn.1009-7147.2010.02.004.
doi: 10.3969/j.issn.1009-7147.2010.02.004
|
[17] |
Lim M, Xia Y, Bettegowda C, et al. Current state of immunotherapy for glioblastoma[J]. Nat Rev Clin Oncol, 2018, 15(7): 422-442. DOI: 10.1038/s41571-018-0003-5.
doi: 10.1038/s41571-018-0003-5
|
[18] |
Hara A, Kanayama T, Noguchi K, et al. Treatment strategies based on histological targets against Invasive and resistant glioblastoma[J]. J Oncol, 2019, 2019:2964783. DOI: 10.1155/2019/2964783.
doi: 10.1155/2019/2964783
|
[19] |
D'Amico RS, Englander ZK, Canoll P, et al. Extent of resection in glioma—a review of the cutting edge[J]. World Neurosurg, 2017, 103:538-549. DOI: 10.1016/j.wneu.2017.04.041.
doi: S1878-8750(17)30536-3
pmid: 28427971
|
[20] |
彭耀南, 张协军, 沙小松, 等. 43例复发脑胶质瘤病理进展的影响因素分析[J]. 临床医学研究与实践, 2020, 5(16): 22-23, 26. DOI: 10.19347/j.cnki.2096-1413.202016008.
doi: 10.19347/j.cnki.2096-1413.202016008
|
[21] |
Baumert BG, Hegi ME, van den Bent MJ, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study[J]. Lancet Oncol, 2016, 17(11): 1521-1532. DOI: 10.1016/S1470-2045(16)30313-8.
doi: 10.1016/S1470-2045(16)30313-8
|